Trends in the Administration of Tranexamic Acid for Postpartum Hemorrhage
Recruiting
Observational Study
Postpartum Hemorrhage
Delivery Complication
Cesarean Section Complications
Perinatal Problems
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Sex
- Female
- Study type
- Observational
- Participants needed
- 648 (estimated)
- Sponsor
- Mahidol University · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Postpartum hemorrhage (PPH) is the global leading cause of maternal death, with 20-30% of maternal deaths in Thailand linked to hemorrhage. The WOMAN Trial (2017) provided strong evidence that administering tranexamic acid (TXA)within three hours of bleeding onset lowered PPH-related mortality by 31%. Consequently, the World Health Organization (WHO) updated its guidelines, recommending TXA as par…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* 1\. Patients underwent cesarean delivery with primary postpartum hemorrhage
Exclusion Criteria:
1. Gestational age at less than 24 weeks
2. Absence of the anesthetic record
3. Received tranexamic acid in the antepartum period
4. Blood loss less than 1,000 ml
Contacts